Kymera Therapeutics (KYMR) Q3 2024 earnings summary

Executive summary

• KT-621, a first-in-class oral STAT6 degrader, entered phase I clinical trials, marking the first STAT6 medicine to reach this stage, with data expected in the first half of 2025.

• KT-474 (IRAK4 degrader) advanced into expanded phase II-B studies with Sanofi, targeting accelerated registration timelines and completion by mid-2026.

• KT-295 was selected as the new lead TYK2 degrader candidate, with phase I trials planned for the first half of 2025.

• Strategic focus shifted further toward immunology, with oncology programs KT-333 and KT-253 to advance beyond phase I only with partners.

• Cash, cash equivalents, and marketable securities totaled $911 million as of September 30, 2024, supporting operations into mid-2027.

Financial highlights

• Recognized $3.7 million in collaboration revenue for Q3 2024, all from the Sanofi partnership.

• Research and development expenses rose to $60.4 million in Q3 2024, while general and administrative expenses increased to $15.5 million.

• Net loss was $62.5 million for Q3 2024, compared to $52.9 million in Q3 2023.

• Cash, cash equivalents, and investments totaled $911 million as of September 30, 2024.

• Impairment charge of $4.9 million in 2024 due to exiting a facility lease.

Outlook and guidance

• KT-621 phase I SAD/MAD results expected in the first half of 2025, with subsequent patient studies planned.

• KT-295 phase I trial remains on track to start in the first half of 2025.

• KT-474 phase II-B trial primary completion dates set for first half and mid-2026 for HS and AD, respectively.

• Cash runway anticipated into mid-2027, supporting multiple clinical milestones.

• Additional immunology pipeline disclosures anticipated in 2025.